Overview
Dr. Reitman’s clinical interests include radiotherapy for primary and metastatic tumors of the brain and spine. He is also interested in basic and translational research studies to develop new treatment approaches for pediatric and adult brain tumors. He uses genomic analysis, radiation biology studies, and genetically engineered animal models of cancer to carry out this research
Current Appointments & Affiliations
Assistant Professor of Radiation Oncology
·
2021 - Present
Radiation Oncology,
Clinical Science Departments
Assistant Professor of Pathology
·
2022 - Present
Pathology,
Clinical Science Departments
Assistant Professor in Neurosurgery
·
2022 - Present
Neurosurgery,
Neurosurgery
Member of the Duke Cancer Institute
·
2019 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Neurocognitive outcomes in patients with brain metastases: a systematic review.
Journal Article Lancet Oncol · December 2025 Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Altho ... Full text Link to item CiteAuthors' View-FLASH Radiation: A Game-Changer in Pediatric Brain Tumor Treatment?
Journal Article Int J Radiat Oncol Biol Phys · November 1, 2025 Full text Link to item CiteInvestigating the FLASH Effect in a Rat Brain Organotypic Model With a Novel High-Energy Electron Beam.
Journal Article Int J Radiat Oncol Biol Phys · October 10, 2025 PURPOSE: Ultrahigh dose rate (FLASH) radiation therapy is reported to reduce normal tissue toxicity while maintaining tumor control; however, mechanism(s) remain obscure. To study FLASH mechanisms in brain tissue, we developed a novel experimental platform ... Full text Link to item CiteRecent Grants
Inflammasomes - a driver of sexual dimorphism to glioma therapies
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030Role of ATRX deficiency as a determinant of topoisomerase 1 inhibitor sensitivity in high grade gliomas
ResearchCo Investigator · Awarded by American Cancer Society, Inc. · 2025 - 2028Modulation of STING to enhance the efficacy of treatments for diffuse midline glioma
ResearchPrincipal Investigator · Awarded by Alex's Lemonade Stand · 2024 - 2028View All Grants
Education, Training & Certifications
Duke University, School of Medicine ·
2014
M.D.
Duke University, School of Medicine ·
2012
Ph.D.